期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PAD方案治疗多发性骨髓瘤的效果观察

下载PDF
导出
摘要 目的探讨PAD方案治疗多发性骨髓瘤的临床效果。方法在医院2013年9月至2016年4月诊治的多发性骨髓瘤患者中抽取76例作研究对象,经随机抽签法分组,治疗组(n=38)应用硼替佐米、地塞米松联合表柔比星(PAD方案)治疗,对照组(n=38)应用长春地辛联合表柔比星、地塞米松、沙利度胺(VADT方案)治疗,对比两组患者临床疗效以及初始疗效、最佳疗效的中位时间。结果治疗组治疗有效率是68.42%,初始疗效的中位时间、最佳疗效的中位时间分别是(4.13±0.45)d、(4.26±0.45)d;对照组治疗有效率是44.74%,初始疗效的中位时间、最佳疗效的中位时间分别是(3.26±0.47)d、(3.62±0.15)d;两组指标的组间对比均有统计学差异(P<0.05或P<0.01)。结论 PAD方案治疗多发性骨髓瘤的临床效果肯定,且起效快,值得借鉴。
作者 陈凤华
机构地区 吉林省四平市中心人民医院
出处 《中国医药指南》 2018年第16期136-137,共2页 Guide of China Medicine
关键词 PAD方案 多发性骨髓瘤 初始疗效中位时间 最佳疗效中位时间
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献6

二级参考文献69

  • 1HENRY DH, COSTA L, GOLDWASSER F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma[J]. Journal of Clinical Oncology, 2011, 29(9): 1125-1132.
  • 2RAJKUMAR SV, JACOBUS S, CALLANDER NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diag- nosed multiple myeloma: an open-label randomised eontrolled trial[J]. The Laneet Oneology, 2010, 11(1): 29-37.
  • 3PALUMBO A, BERTOLA A, FALCO P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma[J]. The Hematology Journal, 2013, 5(1): 318-324.
  • 4DIMOPOULOS M, HAMILOS G, ZOMAS A, et al. Pulsed ey- clophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma[J]. The Hematology Journal, 2013, 5(2): 112-117.
  • 5KYLE RA, DURIE BGM, RAJKUMAR SV, et al. Monoelonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk faetors for progression and guidelines for monitoring and management[J]. Leukemia, 2010, 24(6): 1121-1127.
  • 6MATEOS MV, ORIOL A, MARTfNEZ-LOPEZ J, et al. Borte- zomib, mclphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenanee treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial[J]. The Lancet Oncology, 2010, 11(10): 934-941.
  • 7CAVO M, TACCHETTI P, PATRIARCA F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induetion therapy before, and consolida- tion therapy after, double autologous stem-eell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study [J]. The Lancet, 2010, 376(9758): 2075-2085.
  • 8MOREAU P, PYLYPENKO H, GROSICKI S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study[J]. The Lancet Oncology, 2011, 12(5): 431-440.
  • 9MATEOS MV, RICHARDSON PG, SCHLAG R, et al. Borte- zomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updat- ed follow-up and impact of subsequent therapy in the phase III VISTA trial [J]. Journal of Clinical Oncology, 2010, 28 (13): 2259-2266.
  • 10SONNEVELD P, SCHMIDT-WOLF IGH, VAN DER HOLT B, et al. Bortezomib induction and maintenance treatment in pa- tients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial[J]. Journal of Clinical Oncology, 2012, 30(24): 2946-2955.

共引文献38

中国医药指南
2018年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部